Shilpa Medicare Ltd

Shilpa Medicare Files First Transdermal Patch ANDA 📈 $112M US Market Opportunity

• Filed first transdermal patch ANDA with USFDA on February 6, 2026

• Generic version of Neupro® in six strengths (1-8 mg/24h)

• Targets $112 million US market opportunity

• Indicated for Parkinson's disease and Restless Legs Syndrome

• Developed at USFDA and European-approved Unit VI facility in Bengaluru

• Represents company's first transdermal patch dosage form

• Features once-daily, patient-friendly controlled release formulation